<unk>  (marketed under the trade name Glybera) is a gene therapy treatment that compensates for lipoprotein lipase deficiency (LPLD), which can cause severe pancreatitis. In July 2012, the European Medicines Agency recommended it for approval, the first recommendation for a gene therapy treatment in either Europe or the United States. The recommendation was endorsed by the European Commission in November 2012 and commercial rollout is expected in late 2013.
Alipogene tiparvovec
Fosamprenavir
Abacavir lamivudine
Telaprevir
Remdesivir
Daclatasvir
Nevirapine
Cemiplimab-rwlc